300009 logo

Anhui Anke Biotechnology (Group) Co., Ltd. Stock Price

SZSE:300009 Community·CN¥18.1b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 5 Fair Values set on narratives written by author

300009 Share Price Performance

CN¥10.83
1.61 (17.46%)
CN¥10.83
1.61 (17.46%)
Price CN¥10.83

300009 Community Narratives

There are no narratives available yet.

Snowflake Analysis

Flawless balance sheet established dividend payer.

1 Risk
1 Reward

Anhui Anke Biotechnology (Group) Co., Ltd. Key Details

CN¥2.6b

Revenue

CN¥625.2m

Cost of Revenue

CN¥2.0b

Gross Profit

CN¥1.3b

Other Expenses

CN¥668.7m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
0.40
75.74%
25.95%
0%
View Full Analysis

About 300009

Founded
2000
Employees
2647
CEO
Jian Ping Yao
WebsiteView website
www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. The company offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, immunohistochemical, sperm DNA fragmentation staining, leptin, and immunohistochemical diagnostic kits. In addition, the company offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care products, including anti-aging, masks, essential liquids, and mouthwash; and sybthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, it provides autosomal, sex chromosome, and other kits; paternity testing, tumor biological immunotherapy technology, and DNA testing services. Additionally, the company offers monoclonal antibody drugs, such as Trastuzumab to treat patients with breast and gastric cancers under the ANTRASTUIN brand; Bevacizumab, an anti-VFDF product; ANKEBIO anti-PD1; and anti-covid19 products. The company was founded in 2000 and is based in Hefei, China.

Recent 300009 News & Updates

Recent updates

No updates